Back to Journals » Journal of Inflammation Research » Volume 13

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

Authors Kacar M, Savic S, van der Hilst JCH

Received 14 January 2020

Accepted for publication 20 February 2020

Published 9 March 2020 Volume 2020:13 Pages 141—149


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ning Quan

Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3

1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, Belgium

Correspondence: Jeroen CH van der Hilst
Department of Infectious Diseases and Immunity, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, Belgium
Tel +32 11309485

Abstract: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%– 10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.

Keywords: familial mediterranean fever, Canakinumab, anti-IL1 therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]